Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose.
Continue Reading Article
News provided by Amgen on 7/11/16
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such
In a recent article at BenefitsPRO, Dan Cook talks about the movement to have employers “rise up and fight their own battles with the drug
“Today, one in four Americans who need prescription drugs struggle to afford them — one in four,” president Joe Biden. The last two administrations have
